VMQ StocksFor the value investor looking to harness academic research in
an actively managed portfolio
Bits and BipsNewsletter delivering insights on linking traditional finance, macro trends and cryptocurrency opportunities to help investors build stronger, more diversified portfolios.
All premium products come with free basic membership.
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company’s product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer’s disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.
Learn more about NextCure Inc's (NXTC) stock grades for Momentum, Growth and Estimate Revisions and determine whether this Biotechnology & Medical Research stock meets your investment needs.
Jenna Brashear
Financial Summary
Share Statistics
NXTC
Industry Median
Percentile (All Stocks)
Market Cap (Mil)
$15.0
$252.6
8%
Shares Out (Mil)
5.2
52.3
14%
Institutional Ownership
96.4%
92.1%
70%
Float (Mil)
1.9
40.2
5%
Beta
1.42
0.95
80%
Avg Daily Volume (000s)
552
455
61%
Price Change (52-week)
(17.3%)
52.9%
32%
Growth
NXTC
Industry Median
Percentile (All Stocks)
Sales (5yr)
na
13.6%
na
Net Income (5yr)
(8.8%)
(9.9%)
30%
EPS (5yr)
(4.2%)
16.0%
26
Dividends (5yr)
na
0.0%
na
Cash Flow (5yr)
13.2%
(15.6%)
71%
Estimates
Qtrly
Current Fiscal Year
Next Fiscal Year
# of Estimates
4
4
4
Current EPS
($1.923)
($7.463)
($7.065)
Month Ago EPS
($1.920)
($7.323)
($8.310)
# Rev Up
1
1
1
# Rev Down
0
0
0
Three Months Ago EPS
($2.000)
($8.207)
($6.310)
Year/Year Chg
2.8%
(62.0%)
(77.9%)
Financials
NXTC
Industry Median
Percentile (All Stocks)
Sales (TTM) (Mil)
na
$38
na
Net Income (TTM) (Mil)
($55)
($43)
15%
EPS (TTM)
($15.317)
($1.600)
3%
Operating Cash Flow (TTM) (Mil)
($50)
($31)
9%
Net Cash Flow (TTM) (Mil)
($7)
$5
33%
Long-Term Debt (Q1) (Mil)
$4
$5
23%
Enterprise Value (Q1) (Mil)
($1)
$180
3%
Valuation
NXTC
Industry Median
Percentile (All Stocks)
P/B
0.56
2.56
10%
P/E
na
19.0
na
Dividend Yield
na
0.0%
na
PEG (5yr hist)
na
0.9
na
Ratios
NXTC
Industry Median
Percentile (All Stocks)
Gross Margin
na
63.8%
na
Net Margin
na
(67.3%)
na
ROA
(104.0%)
(49.8%)
5%
ROE
(132.4%)
(55.5%)
7%
Liabilities to Assets
29.7%
30.3%
21%
F-Score
1
3
1%
NextCure, Inc. did not pass any screens on 7/31/2026.
Looking for access to this powerful feature? Take the first step in becoming an A+ Investor today.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors